Alnylam PharmaceuticalsALNY
Recorded

Alnylam Pharmaceuticals Investor update

Review the key takeaways and the transcript of this earnings call.

Period 0Duration1 hr 30 minParticipants7

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello everyone, and welcome to this RNAi Roundtable. We're happy you were able to join us. I'd now like to pass the call over to the company.

Josh BrodskyVP of Investor Relations

Good morning, everyone. Thank you for joining us for today's RNAi Roundtable, where we'll be discussing brezosiran, also known as ALN-HTT02, which is in development for the treatment of Huntington's disease. I'm Josh Brodsky, Vice President of Investor Relations at Alnylam. With me today are Pushkal Garg, our Chief Research and Development Officer, Kevin Sloan, Vice President of Development Programs and Program Lead for brezosiran, and Toby Ferguson, Senior Vice President and Head of the Neuroscience Therapeutic Area at Alnylam. We're also thrilled to be joined by Dr. Gill Bates, Professor of Molecular Neuroscience and Co-director of the Huntington's Disease Centre at University College London, who will provide perspective on the role of the HTT1a isoform in Huntington's disease biology and why targeting exon 1 may be important for HTT lowering strategies.

Josh BrodskyVP of Investor Relations

Today's RNAi Roundtable is part of a series of roundtable webinars that we've been hosting to review progress across various clinical stage development programs. Roundtables are archived on both the Capella section and events page of our website if you'd like to access a presentation or view the replay. At the conclusion of today's presentations, Pushkal will moderate a Q&A session. If you'd like to submit a question, you can do so at any time during the event by using the Q&A feature directly within the webcast platform. Alnylam has engaged Dr. Bates as an independent academic speaking in her personal scientific capacity. She is not speaking on behalf of University College London or UCL Consultants today. Nothing said by Dr. Bates constitutes investment advice, nor should it be relied on in making investment decisions.

Josh BrodskyVP of Investor Relations

As a reminder, we will be making forward-looking statements during the webinar, and we encourage you to read our most recent SEC filings for a more complete discussion of our risk factors. With that, I'll now turn it over to Pushkal to kick things off.

Pushkal GargChief Research and Development Officer

Pushkal? Thanks, Josh, and welcome everyone to today's RNAi Roundtable on brezosiran, previously known as ALN-HTT02.

Pushkal GargChief Research and Development Officer

This program takes a unique approach to tackling a very devastating inherited neurodegenerative disorder, Huntington's disease. As many of you know, Alnylam spent over two decades pioneering RNA interference as a new class of medicines. RNAi allows us to silence disease-causing genes with a highly specific, potent, durable, and reversible approach, enabling infrequent administration. We've translated that science into six approved medicines, and we continue to expand the potential of RNAi into new targets and tissues. Our R&D strategy is focused on maximizing that potential by combining human genetics, advances in tissue delivery, and continued innovation in platform design. We apply those capabilities with discipline, pursuing genetically validated targets in serious diseases where we believe RNAi can have meaningful impact.

Pushkal GargChief Research and Development Officer

To date, this strategy has yielded what we believe is one of the most robust pipelines in the biotech industry. With over 25 programs spanning rare specialty and prevalent indications across multiple therapeutic areas, we believe this pipeline underscores the depth of opportunity we have at Alnylam to enable growth and deliver more transformative medicines to patients. We're now entering a period of significant clinical momentum across that pipeline. The Huntington's disease data we're discussing today are part of a growing cadence of important clinical readouts expected over the next several years. These will be accompanied by an increasing number of programs moving into phase III development as we continue to build towards our Alnylam 2030 goals. As I mentioned, a major advance in extending RNAi beyond the liver has been our C16-siRNA delivery platform, which opened the door to targeting the central nervous system.

Pushkal GargChief Research and Development Officer

We've seen robust targeting engagement and broad biodistribution across the CNS in non-human primates. We've seen that now reproducibly translate into knockdown of disease-causing proteins in the CNS, first with mivelsiran, our investigational APP targeting program, and as we've just announced with initial phase I-B data now with brezosiran, which targets huntingtin. This successful translation has provided the confidence for us to build a growing pipeline of investigational CNS-targeted RNAi therapeutics in collaboration with our colleagues at Regeneron, including programs in Alzheimer's disease, Huntington's disease, ALS, and Parkinson's. Brezosiran is part of our efforts to apply RNAi to serious neurologic diseases where meaningful new treatment options are desperately needed. With that, I'd like to hand it over to Kevin Sloan, who'll discuss the unmet need in Huntington's disease and the approach that we're taking with brezosiran.

Kevin SloanVP of Development Programs and Program Lead for Brezosiran

Kevin? Thanks, Pushkal. I'm Kevin Sloan, the program lead for brezosiran at Alnylam.

Kevin SloanVP of Development Programs and Program Lead for Brezosiran

It's a pleasure to discuss the exciting progress and promise of this program with you all today, as we're working with urgency to improve the lives of people living with Huntington's disease. Before I begin, I'd like to note that we've been partnering closely with the broader Huntington's disease community throughout the life of this program and have sought to learn from the many efforts that have come before us. We're very grateful for the support we've received to date and are committed to maintaining that partnership as we move forward. Huntington's disease is a progressive, fatal, monogenic neurodegenerative disease. It affects movement, where patients can experience chorea or rapid involuntary muscle movements, incoordination, and falls. It also affects thinking, which can manifest as executive dysfunction and memory loss.

Kevin SloanVP of Development Programs and Program Lead for Brezosiran

It can affect mood, leading to depression, apathy, personality changes, and suicidality. Symptoms of the disease typically appear in midlife during prime working and family years. Average lifespan is shortened to approximately 10-30 years from diagnosis. Because HD is inherited in an autosomal dominant pattern, each child of an affected parent has a 50% chance of inheriting the disease-causing mutation. We estimate that there are more than 100,000 symptomatic patients globally, with many more individuals who may be pre-symptomatic or undiagnosed. Huntingtin is a well-known genetically validated target for Huntington's disease, which is caused by an expanded CAG repeat in the first exon of the huntingtin gene. A normal huntingtin allele contains 26 or fewer CAG repeats. Individuals who inherit an allele with 40 or more repeats are expected to develop HD during their lifetime.

Kevin SloanVP of Development Programs and Program Lead for Brezosiran

Now, the length of the inherited repeat is only part of the underlying biology. The CAG repeat tract can expand further over an individual's lifetime through a process called somatic instability. Those expanding CAG repeats are thought to drive accumulation of mutant huntingtin proteins that are toxic to cells, including full-length mutant huntingtin and also a shorter mutant huntingtin isoform called HTT1a. Both of these protein species are believed to contribute to neuronal toxicity and the downstream pathophysiology of HD. Importantly, the disease process begins decades before symptoms. Changes in CSF or imaging biomarkers can emerge well before cognitive and motor clinical signs. Clinical signs precede the functional decline and increasing loss of independence that ultimately defines later stage disease. This long disease course may provide an opportunity to intervene before significant functional decline.

Kevin SloanVP of Development Programs and Program Lead for Brezosiran

Yet Huntington's disease is often diagnosed only after clinical signs or symptoms have emerged, underscoring the urgency of identifying and treating earlier in the course of disease. As I've mentioned, the root cause is an expanded CAG repeat in the first exon of the huntingtin gene or exon 1. Due to alternative splicing during transcription, the mutant gene can give rise to more than one protein species, a longer full-length mutant huntingtin encoded by 67 exons, and a shorter mutant HTT1a isoform encoded by only that first exon. Both full-length mutant huntingtin and HTT1a are implicated as toxicity drivers, and Dr. Bates will go deeper into the biology of HTT1a and preclinical evidence supporting its role as a driver of disease. Importantly, not all past or current huntingtin lowering drug development approaches have been able to effectively address HTT1a.

Kevin SloanVP of Development Programs and Program Lead for Brezosiran

That's because many of those target sequences that fall downstream of exon 1, and thereby are only able to lower the longer full-length mutant huntingtin protein. When we designed brezosiran, we considered several possible strategies. Lowering HTT1a alone, lowering full-length huntingtin alone, or take an inclusive approach to lower both. We ultimately selected the latter, taking an exon 1 targeting approach designed to lower all relevant huntingtin species in the CNS, including both full-length mutant huntingtin and HTT1a. Huntington's disease researchers and industry partners have long been trying to tackle this disease, and huntingtin lowering has been the primary targeting strategy for therapeutic development since the responsible gene was identified in 1993. However, progress with huntingtin lowering has been hampered by technical issues across several different drug development modalities.

Kevin SloanVP of Development Programs and Program Lead for Brezosiran

Unfortunately, the molecule and/or platform-related toxicities associated with some early-generation antisense oligonucleotide and small molecule splice modulators is often conflated with the safety of huntingtin lowering itself. For example, some huntingtin lowering ASOs have encountered exposure-related safety signals, including increases in a biomarker of neuroaxonal injury called neurofilament light or NfL, even with relatively limited levels of huntingtin lowering below 50%. The ASO tominersen, which was designed to lower full-length mutant huntingtin and wild-type huntingtin, was reported to cause dose-dependent NfL increases within six months, despite moderate CSF mutant huntingtin reductions. The ASO WVE-003, which was designed to lower full-length mutant huntingtin but spare wild-type huntingtin through an allele selective targeting, was also reported to cause large increases in NfL within six months, despite modest CSF mutant huntingtin reductions. A couple of key questions remain unanswered. First, how much mutant huntingtin lowering may be needed to maximize efficacy?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day